Moreover, the downregulation of IGF‐1R expression in DLBCL can also reduce Hippo–YAP signaling activation, which offers novel therapeutic insights for DLBCL treatment.78 This evidence concerns the gene YAP1 and diffuse large B-cell lymphoma.